While Phase II-III studies include small datasets, comprising several hundred to several thousand patients, they provide the data necessary for drug approvals. The FDA approval of a drug is contingent on the drug company designing and implementing a post-marketing, or Phase IV study, designed to obtain additional data in a larger, real-world patient population. Join Dr. Keith Coffee as he explores how and why practicing physicians agree to participate in Phase IV studies. He will also address the common concerns many physicians raise regarding time spent and reimbursement for participating in these studies.
Explore related content and topics
White Paper
PRA INSIGHTS REPORT 2018 ISPOR-North America Survey Results
A summary of survey results from ISPOR’s Annual North America meeting, where we gathered insights on important developments in the real world…
Page
Embedded Solutions
Our Embedded Solutions™ model helps clients execute their product portfolios more efficiently, with greater control, standardization, consistency,…
Webcast
THE INSIGHT SERIES: Introduction to Myths and Misconceptions of Late Phase – Part 1
Late phase research has changed substantially over the past decade. During this period of innovation and development, many myths and misconceptions…